Naganari Ohkura

Title: Naganari Ohkura: Innovator in Regulatory T Cell Production

Introduction

Naganari Ohkura is a prominent inventor based in Kyoto, Japan. He has made significant contributions to the field of immunology, particularly in the production of regulatory T cells (Tregs). His innovative work has the potential to impact therapeutic strategies for various autoimmune diseases.

Latest Patents

Naganari Ohkura holds a patent for a novel compound and method for producing regulatory T cells. The patent describes a compound that exhibits CDK8 and/or CDK19 inhibitory activity. The treatment of T cells with this inhibitor induces the expression of Foxp3 in the T cells. Furthermore, Foxp3T cells can be induced by treating them with the CDK8 and/or CDK19 inhibitor in vitro, thereby facilitating the induction of Tregs. He has 1 patent related to this groundbreaking research.

Career Highlights

Throughout his career, Naganari Ohkura has worked with esteemed institutions such as Kyoto University and Astellas Pharma GmbH. His research has focused on the mechanisms of T cell regulation and the development of therapeutic approaches to enhance immune responses.

Collaborations

Naganari Ohkura has collaborated with notable colleagues in his field, including Shimon Sakaguchi and Norihisa Mikami. These collaborations have further enriched his research and contributed to advancements in immunology.

Conclusion

Naganari Ohkura's innovative work in the production of regulatory T cells showcases his dedication to advancing medical science. His contributions have the potential to lead to significant breakthroughs in the treatment of autoimmune diseases.